Iveric Bio (ISEE) PT Raised to $14 at Credit Suisse, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ISEE Hot Sheet
Price: $39.95 --0%
Rating Summary:
4 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Rating Summary:
4 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 1
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth raised the price target on Iveric Bio (NASDAQ: ISEE) to $14.00 (from $13.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades PagSeguro (PAGS) to Neutral
- Encore Capital Inc. (ECPG) PT Raised to $140 at Citizens on Material Upside to EPS, KPI Estimates
- Fidelity National Information Services (FIS) PT Lowered to $46 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Credit Suisse, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
